CD22-CAR therapy shows activity in rel/ref B-ALL

Print Friendly, PDF & Email


Micrograph showing B-ALL
Researchers say they have reported the first results demonstrating clinical activity of a CD22-directed chimeric antigen receptor (CAR) T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL). The team conducted a phase 1 study of the therapy in 21 children and adults with relapsed/refractory B-ALL. Twelve patients achieved a complete response... [Read Article]
Print Friendly, PDF & Email

FDA approves generic clofarabine

Print Friendly, PDF & Email


Micrograph showing
acute lymphoblastic leukemia
The US Food and Drug Administration (FDA) has approved Dr. Reddy’s Laboratories Ltd.’s Clofarabine Injection, a therapeutic equivalent generic version of Clolar® (clofarabine) Injection. The generic drug is now approved to treat patients age 1 to 21 who have relapsed or refractory acute lymphoblastic leukemia and have received at... [Read Article]
Print Friendly, PDF & Email

Overcoming resistance to proteasome inhibitors

Print Friendly, PDF & Email


Micrograph showing
multiple myeloma
Preclinical research has revealed a potential method of overcoming resistance to proteasome inhibitors. By studying a rare genetic disease known as NGLY1 deficiency, researchers have gained new understanding of resistance to proteasome inhibitors. The team found that treatment with a NGLY1 inhibitor can enhance the activity of the proteasome... [Read Article]
Print Friendly, PDF & Email

ATLG fights GVHD but reduces PFS, OS

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
Results of a phase 3 trial suggest rabbit anti-T lymphocyte globulin (ATLG) can reduce graft-versus-host disease (GVHD) but also decrease survival in patients who have received a hematopoietic stem cell transplant (HSCT) from a matched, unrelated donor. In this randomized trial, ATLG significantly decreased the incidence... [Read Article]
Print Friendly, PDF & Email

CHMP recommends new formulation of pegaspargase

Print Friendly, PDF & Email


Micrograph showing ALL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorization for lyophilized pegaspargase (ONCASPAR). If approved, the product would be used as a component of antineoplastic therapy in patients of all ages who have acute lymphoblastic leukemia (ALL). The product is a freeze-dried formulation... [Read Article]
Print Friendly, PDF & Email

Natural selection opportunities tied to cancer rates

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Countries with the lowest opportunities for natural selection have higher cancer rates than countries with the highest opportunities for natural selection, according to a study published in Evolutionary Applications. Researchers said this is because modern medicine is enabling people to survive cancers, and their genetic... [Read Article]
Print Friendly, PDF & Email

Study supports prophylaxis in kids with ALL

Print Friendly, PDF & Email


A patient who received
prophylaxis pictured with
study authors Sima Jeha, MD,
and Joshua Wolf, MD
Photo from Seth Dixon,
St. Jude Children’s
Research Hospital
Results of an observational study support targeted antibacterial prophylaxis in children undergoing induction therapy for acute lymphoblastic leukemia (ALL). Prophylaxis effectively prevented febrile neutropenia and systemic infection in... [Read Article]
Print Friendly, PDF & Email